Difference between revisions of "Vismodegib (Erivedge)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
Warner-admin (talk | contribs) m (Text replacement - "Basal cell carcinoma (BCC)" to "Cutaneous basal cell carcinoma") |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Cutaneous basal cell carcinoma]] |
*[[SMO or PTCH-1 (Hedgehog)|Hedgehog pathway-mutated tumors (tissue-agnostic)]] | *[[SMO or PTCH-1 (Hedgehog)|Hedgehog pathway-mutated tumors (tissue-agnostic)]] | ||
| Line 15: | Line 15: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *1/30/2012: Initial FDA approval "for the treatment of adults with metastatic [[ | + | *1/30/2012: Initial FDA approval "for the treatment of adults with metastatic [[Cutaneous basal cell carcinoma|basal cell carcinoma]], or with locally advanced [[Cutaneous basal cell carcinoma|basal cell carcinoma]] that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation." |
==Also known as== | ==Also known as== | ||
| Line 30: | Line 30: | ||
[[Category:SMO inhibitors]] | [[Category:SMO inhibitors]] | ||
| − | [[Category: | + | [[Category:Cutaneous basal cell carcinoma medications]] |
[[Category:SMO or PTCH-1 (Hedgehog) medications]] | [[Category:SMO or PTCH-1 (Hedgehog) medications]] | ||
[[Category:FDA approved in 2012]] | [[Category:FDA approved in 2012]] | ||
Revision as of 19:22, 16 August 2018
General information
Class/mechanism: Hedgehog pathway inhibitor. Vismodegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog signal transduction pathway that is clinically relevant in diseases such as basal cell cancer.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Erivedge manufacturer side effect tips[4]
- Vismodegib (Erivedge) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1/30/2012: Initial FDA approval "for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation."
Also known as
- Code name: GDC-0449
- Brand name: Erivedge